ATE305052T1 - Drogen untersuchungssystem - Google Patents

Drogen untersuchungssystem

Info

Publication number
ATE305052T1
ATE305052T1 AT97905316T AT97905316T ATE305052T1 AT E305052 T1 ATE305052 T1 AT E305052T1 AT 97905316 T AT97905316 T AT 97905316T AT 97905316 T AT97905316 T AT 97905316T AT E305052 T1 ATE305052 T1 AT E305052T1
Authority
AT
Austria
Prior art keywords
investigation system
drug
drug investigation
gilbert
possessing
Prior art date
Application number
AT97905316T
Other languages
English (en)
Inventor
Brian Burchell
Original Assignee
Univ Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9604480.5A external-priority patent/GB9604480D0/en
Priority claimed from GBGB9605598.3A external-priority patent/GB9605598D0/en
Application filed by Univ Dundee filed Critical Univ Dundee
Application granted granted Critical
Publication of ATE305052T1 publication Critical patent/ATE305052T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Primary Health Care (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
AT97905316T 1996-03-01 1997-03-03 Drogen untersuchungssystem ATE305052T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9604480.5A GB9604480D0 (en) 1996-03-01 1996-03-01 Assay system
GBGB9605598.3A GB9605598D0 (en) 1996-03-16 1996-03-16 Drug trial assay system
PCT/GB1997/000577 WO1997032042A2 (en) 1996-03-01 1997-03-03 Drug trial assay system

Publications (1)

Publication Number Publication Date
ATE305052T1 true ATE305052T1 (de) 2005-10-15

Family

ID=26308851

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97905316T ATE305052T1 (de) 1996-03-01 1997-03-03 Drogen untersuchungssystem

Country Status (6)

Country Link
US (1) US20070009920A1 (de)
EP (1) EP0894145B1 (de)
AT (1) ATE305052T1 (de)
AU (1) AU2224197A (de)
DE (1) DE69734237T2 (de)
WO (1) WO1997032042A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1084271A2 (de) 1998-05-07 2001-03-21 Axys Pharmaceuticals, Inc. Typisierung des humanen udp-glucuronosyltransferase 1 (ugt1) genes
EP1352970B1 (de) * 2000-12-12 2010-06-02 Nagoya Industrial Science Research Institute Verfahren zur abschätzung des risikos der expression einer durch die verabreichung einer verbindung, die entweder per se durch ugt1a1 metabolisiert wird oder deren zwischenverbindung durch das enzym metabolisiert wird, hervorgerufenen unerwünschten arzneimittelwirkung
ES2308208T3 (es) 2003-05-30 2008-12-01 University Of Chicago Metodos y composiciones para predecir la toxicidad del irinotecano.
EP3257949A1 (de) * 2005-06-15 2017-12-20 Complete Genomics Inc. Nukleinsäureanalyse durch zufällige mischungen von nichtüberlappenden fragmenten
JPWO2007055261A1 (ja) * 2005-11-10 2009-04-30 財団法人新産業創造研究機構 Ｕｇｔ１ａ１遺伝子多型の検査法
JP5372734B2 (ja) * 2009-12-28 2013-12-18 シスメックス株式会社 検体処理システム及び検体搬送ユニット

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260196A (en) * 1987-11-25 1993-11-09 City Of Hope Method for the diagnosis of Tourette syndrome and associated disorders
WO1992012987A1 (en) * 1991-01-10 1992-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services The genetic locus ugt1 and a mutation therein

Also Published As

Publication number Publication date
DE69734237T2 (de) 2006-07-06
DE69734237D1 (de) 2005-10-27
EP0894145A2 (de) 1999-02-03
US20070009920A1 (en) 2007-01-11
WO1997032042A2 (en) 1997-09-04
EP0894145B1 (de) 2005-09-21
AU2224197A (en) 1997-09-16
WO1997032042A3 (en) 1997-11-20

Similar Documents

Publication Publication Date Title
EP1009440A4 (de) Methode zur hemmung immunstimulatorischer mit dna assoziierter antworten
ATE202487T1 (de) Mono- oder polyfunktionelle konjugate von polylysine
ATE234092T1 (de) 2-alkylpyrrolidine
MX9800625A (es) Marcfortinas y paraherquamidas antiparasitarias.
EP0923243A4 (de) Bearbeitungsanlage, bearbeitungsverfahren, splissungsanlage, splissungs- verfahren, kodieranlage und kodierverfahren
BR9609176A (pt) Composi-{es de agente biolÄgico
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
ATE213005T1 (de) Kontinuierliches polymerisationverfahren von polyamiden
SE9404250D0 (sv) Affinity separation method
ATE244018T1 (de) Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimer
DK1071433T3 (da) 2',2'-difluornucleosider til immunosuppressiv behandling og kombinationspræparater
NO972391L (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
AP9901607A0 (en) Method and apparatus for continuous flow isoelectric focusing for
DE69022926D1 (de) Virtuelle Mikrophonanlage und dafür bestimmtes Verfahren.
DE69714504D1 (de) Benzothiopene, diese enthaltende Zubereitungen und Verfahren
ATE305052T1 (de) Drogen untersuchungssystem
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
DK0929299T3 (da) Substituerede 1,2,3,4-tetrahydro-2-dibenzofuranaminer og 2-aminocyclohepta-(b)benzofuraner
NL1007401A1 (nl) Behandelinrichting voor afvalgas.
GB9619520D0 (en) Bipolar operational transconductance amplifier
AU9334098A (en) Molecular diagnostic of glaucomas associated with chromosomes 1, and method of treatment thereof
DK0647654T3 (da) Anomere fluor-ribosylaminer
PL319024A1 (en) 4-thia-1-azabicyclo(3.2.0) heptane-3-imino-2-isopropylideno-7-ketoanalgones of beta-lactames, method of obtaining them and their application
FR2680714B1 (fr) Unites de maintien et de calage et ensemble forme de telles unites.
Lee et al. Stress Analysis of Dental Implant System Using Homogenization Technique

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties